Compare Ginkgo Bioworks Holdings Inc (DNA) vs iShares S&P GSCI Commodity-Indexed Trust ETF (GSG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs iShares S&P GSCI Commodity-Indexed Trust ETF — how do they compare? Ginkgo Bioworks Holdings Inc trades at $13 (market cap $763.64M), while iShares S&P GSCI Commodity-Indexed Trust ETF trades at $36.08 (market cap $1.02B). The key difference: iShares S&P GSCI Commodity-Indexed Trust ETF is the larger of the two by market cap, and iShares S&P GSCI Commodity-Indexed Trust ETF is trading nearer its 52-week high, Ginkgo Bioworks Holdings Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and iShares S&P GSCI Commodity-Indexed Trust ETF for 40 Days on average.
| DNA | GSG | |
|---|---|---|
Market Cap | $763.64M | $1.02B |
Volume | 3,204,177 | 1,256,221 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $15.83 | $37.15 |
52-Week Low | $5.48 | $22.45 |
Typical Hold Time | 7 Days | 40 Days |
Enterprise Value | $865.59M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $11.34, down 1.13% on the day. The technical outlook is bullish based on moving averages, while oscillators are neutral. Fundamentally, the company reported a net loss of $312.76 million on $170.16 million revenue for 2025, with a negative net income margin of -219.6%. Recent news includes a partnership with TuneLab and a $17.5 million ARPA-H subcontract.
The outlook is challenged by persistent losses and negative cash flow, though strategic partnerships offer growth potential. Analyst sentiment is divided evenly between buy, hold, and sell ratings. Key risks include execution on profitability and high cash burn. The stock presents a speculative opportunity dependent on the company's ability to monetize its technology platform.
GSG trades at $36.08, up 1.23% with neutral technical signals. The company reported strong 2024 results with $51.25M revenue and $69.99M net income, though cash flow turned negative at -$932.80K. Assets remain robust at $968.15M with minimal debt, while recent news highlights commodity market volatility and energy sector exposure as key drivers.
Outlook remains cautious due to commodity price sensitivity and geopolitical risks, though strong profitability and clean balance sheet provide stability. Analyst sentiment is mixed with neutral ratings prevailing, suggesting limited near-term catalysts beyond broader commodity trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About iShares S&P GSCI Commodity-Indexed Trust ETF
GSG is a diversified commodity ETF that tracks the S&P GSCI Total Return Index. It provides exposure to a broad basket of futures, including energy, metals, and agriculture, with a significant weighting toward the energy sector.
Read more on GSG →
